Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hypoxia-inducible factor 1-alpha (HIF-1α) oxygen-dependent degradation (ODD) domain is a critical regulatory region within the HIF-1α protein that mediates its rapid degradation under normoxic conditions [1]. This domain contains specific proline residues (Pro402 and Pro564) that are hydroxylated by prolyl hydroxylase domain (PHD) enzymes in the presence of oxygen [3, 4]. Once hydroxylated, the ODD domain is recognized by the von Hippel-Lindau (VHL) tumor suppressor protein, which acts as part of an E3 ubiquitin ligase complex to target HIF-1α for proteasomal degradation [2]. In hypoxic environments, the lack of oxygen inhibits PHD activity, allowing HIF-1α to escape degradation, accumulate, and translocate to the nucleus to activate genes involved in erythropoiesis, angiogenesis, and anaerobic metabolism [5]. This domain is a focal point for therapeutic intervention; PHD inhibitors stabilize HIF-1α by preventing ODD-mediated degradation to treat anemia, while strategies to enhance its degradation or use the domain for hypoxia-targeted gene delivery are explored for cancer therapy [4, 5].
Inhibition of prolyl hydroxylase (PHD) enzymes prevents the hydroxylation of proline residues within the ODD domain, which blocks the binding of the von Hippel-Lindau (VHL) E3 ubiquitin ligase and prevents the subsequent proteasomal degradation of HIF-1α [2, 3, 5].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxia-inducible factor 1-alpha oxygen-dependent degradation domain (HIF-1α ODD) (HIF-1α ODD).